Precigen, Inc.

NASDAQ:PGEN

Biotechnology

Healthcare
$4.27 -2.08%

-$0.10 today

Market cap
$1.53B
Beta
1.06
P/E (TTM)
-7.1
EPS (TTM)
-$0.65
52W Low $1.39High $5.47

Volume 4.27M

Average 4.72M

PGEN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Precigen, Inc.NASDAQ: PGEN

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 94.9%

Gross margin was 94.9% in Q2 FY2026, up 176.6 pp from a year earlier. On a trailing-twelve-month basis it was 89.6%, up 108.3 pp year over year. Over 3 fiscal years it narrowed by 39.4 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
94.9%+7.3 pp QoQ
Last fiscal yearDec 2025
37.1%+45.8 pp YoY
LTMJun 2026
89.6%+108.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+176.6 pp——
1 year+45.8 pp——
3 years-39.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
37.1%
Year-over-year change
+45.8pp

Gross Margin vs competitors

How PGEN compares with its peers on the latest reported figures

  • PGEN's LTM Jun 2026 gross margin of 89.6% is the 2nd highest of the 7 companies compared; the peer median is 2.8%.
  • Its year-over-year change of +108.3 pp is the 3rd highest of 6, against a peer median of -3.0 pp.
  • Over three fiscal years its change of -39.4 pp compares with a peer median of +18.8 pp.
PGEN Competitors Peer median
Gross Margin for PGEN and competitors
Company Period LTM level YoY 3-year change
DTILPrecision BioSciences, Inc.LTM Mar 202697.0% -3.0 pp-8.0 pp
PGENPrecigen, Inc.LTM Jun 202689.6% +108.3 pp-39.4 pp
ABEOAbeona Therapeutics Inc.LTM Mar 202651.9% —+5.5 pp
EDITEditas Medicine, Inc.LTM Mar 20265.8% +124.1 pp+32.1 pp
RGNXREGENXBIO Inc.LTM Mar 2026-0.1% -76.7 pp+36.5 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-153.7% +248.0 pp-9.0 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-558.9% -202.1 pp+18649.7 pp
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding PGEN) 2.8%-3.0 pp+18.8 pp

Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.27M26.91M6.23M3.93M9.68M
Cost of Revenue53.68M6.34M6.12M4.27M6.1M
Gross Profit(39.41M)20.57M106K(342K)3.59M
Gross Margin-276.2%76.4%1.7%-8.7%37.1%
Research & Development47.93M47.17M48.61M53.07M40.06M
Selling, General & Admin048.01M40.42M41.29M70.13M
Operating Expenses52.54M96.3M99.86M134.69M110.19M
Depreciation & Amortization13.76M10.77M6.67M4.53M3.2M
EBITDA(77.64M)(62.43M)(89.23M)(123.5M)(243.57M)
EBITDA Margin-544.2%-232.0%-1433.3%-3146.4%-2515.2%
Operating Income(91.95M)(75.73M)(99.76M)(135.03M)(106.6M)
Operating Margin-644.5%-281.4%-1602.5%-3440.2%-1100.8%
Interest Income171K133K3.24M1.42M3.22M
Interest Expense18.76M6.77M468K6K3.87M
Other Income / Expenses(19.02M)(4.24M)3.4M7M(144.04M)
Income Before Tax(110.97M)(79.97M)(96.36M)(128.03M)(250.64M)
Pre-Tax Margin-777.8%-297.2%-1548.0%-3261.9%-2588.2%
Income Tax Expense(160K)(189K)(458K)(1.79M)3K
Net Income(92.17M)28.32M(95.9M)(126.24M)(250.64M)
Net Margin-646.0%105.2%-1540.6%-3216.2%-2588.2%
EPS (Basic)(0.47)(0.33)(0.39)(0.47)(1.41)
EPS (Diluted)(0.47)(0.40)(0.39)(0.47)(1.41)
Weighted Avg Shares197.76M200.36M244.54M267.73M304.71M
Weighted Avg Shares (Diluted)197.76M200.36M244.54M267.73M304.71M

Precigen, Inc.

NASDAQ:PGEN

Intrinsic Alpha fair value

Locked

Current Price

$4.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.